Abstract 377MO
Background
The value of surgical removal of lymph nodes prior to initial treatment in patients with locally advanced cervical cancer remains controversial. In this study, we investigated the oncologic outcomes of surgical removal of lymph nodes in patients with locally advanced cervical cancer.
Methods
We systematically searched PubMed, Embase, Science Direct, and the Cochrane Database of Systematic Reviews through December 2023 to examine the impact of Lymph node dissection before initial treatment on patients with locally advanced cervical cancer. We calculated the combined risk ratio (HR) with a 95% confidence interval (CI). This study is registered with PROSPERO (CRD42024492509).
Results
Among 1025 screened articles, 4 studies (836 women) met the inclusion criteria. Our analysis showed that pretreatment lymph node dissection did not affect overall disease survival (OS) in patients with locally advanced cervical cancer (HR=1.11, 95% CI=0.91-1.36, P=0.30). In addition, lymph node dissection did not affect the occurrence of postoperative complications. Lymph node dissection also did not result in delayed postoperative radiotherapy.
Conclusions
ymph node dissection prior to initial treatment for locally advanced cervical cancer clarifies lymph node pathology and does not compromise surgical safety. In particular, removal of larger lymph nodes (>2 cm) helps to define the extent of the radiation field and reduce radiotherapy-related complications. Surgical technique also affects the incidence of postoperative complications to some extent. In summary, in order to obtain the best therapeutic outcome, clinicians need to develop a personalized treatment plan for patients in order to achieve precise treatment and improve the quality of life of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Capital Health Development Research Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
376MO - The impact of crossover to surgery in the no-surgery group on the survival: A post-hoc analysis of the SOC-1 trial
Presenter: Lina Shen
Session: Mini Oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Mini Oral session: Gynaecological cancers
Resources:
Webcast
378MO - Efficacy and safety of disitamab vedotin in treatment of HER2 expressed advanced or recurrent gynecological cancers
Presenter: Dongyan Wang
Session: Mini Oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
379MO - Homologous recombination deficiency testing in Vietnamese patients with ovarian cancer
Presenter: Nam Tran
Session: Mini Oral session: Gynaecological cancers
Resources:
Abstract
Invited Discussant 378MO and 379MO
Presenter: Clare Scott
Session: Mini Oral session: Gynaecological cancers
Resources:
Slides
Webcast
380MO - Role of therapy in the development of second primary malignancies in ovarian cancer survivors: A SEER database analysis
Presenter: Alhareth Alhusban
Session: Mini Oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
381MO - Progression free survival and overall survival in platinum-based chemotherapy alone versus immune checkpoint inhibitor (ICI)-platinum-based chemotherapy combination in first-line treatment for advanced, metastatic or recurrent endometrial adenocarcinoma: A meta-analysis
Presenter: Maria Carmela Vistal
Session: Mini Oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 380MO and 381MO
Presenter: Chee Khoon Lee
Session: Mini Oral session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Session: Mini Oral session: Gynaecological cancers
Resources:
Webcast